Skip to main content
Fig. 5 | Cancer & Metabolism

Fig. 5

From: An iron chelation-based combinatorial anticancer therapy comprising deferoxamine and a lactate excretion inhibitor inhibits the proliferation of cancer cells

Fig. 5

Evaluation of the effect of combined DFO + CHC treatment in Huh7 cells. A Changes in cell confluence observed after DFO monotherapy. B Changes in cell confluence observed after CHC monotherapy. C Changes in cell confluence observed after DFO + CHC treatment. D Combination index of DFO + CHC. Fa, fraction affected; CI, combination index. E Dose-effective curve of the DFO + CHC treatment. F Mixture-algebraic estimate of the DFO + CHC treatment. CI > 1 indicates antagonism, CI =1 indicates additive, CI < 1 indicates synergism. G Evaluation of lactate production upon varying DFO concentrations. Lactate concentration in the medium was measured by a lactose sensor (day 2). *Indicates p < 0.05 compared to control group (one-way ANOVA followed by Tukey’s post hoc test). H LDH expression in HeLa cells and Huh7 cells upon varying DFO concentrations (day3). I Cell viability assay of HeLa cells treated with 2-deoxyglucose (2-DG). IC50 values are 50% cell growth inhibitory concentrations of 2-DG on day 3. Cell viability was analyzed by MTS assay. IC50 was obtained from the following equation: IC50 = 10^[LOG(A/B) × (50-C)/(D-C) + LOG(B)]. A A higher concentration of two values that sandwich IC50. B A lower concentration of two values that sandwich IC50. C Cell viability (%) at (B). D Cell viability (%) at (A). Data are shown as mean ± SD

Back to article page

Cancer & Metabolism

ISSN: 2049-3002